相关实验视频
Updated: Jul 3, 2025
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
50.0K
马格诺林通过抑制ALOX5介导的铁化来缓解DSS诱导的大肠炎
Ting Yao1, Yuan-Yuan Yao1, Jin-Zhi Wang1
1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, China.
The Kaohsiung journal of medical sciences
|February 10, 2024
概括
马格诺林有效地治疗炎症性肠病 (IBD),通过减少铁和调节巨细胞的反应. 这项研究揭示了IBD治疗新策略的潜力.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD) 是一种慢性,无法治愈的疾病,治疗选择有限,癌症风险增加.
- 铁亡,一种受调节的细胞死亡形式,及其相关的损伤相关分子模式 (DAMPs) 通过激活像巨细胞这样的免疫细胞,在IBD病变发生过程中发挥作用.
- 马格诺林因其抗氧化和抗炎性质而闻名,其在IBD中的治疗潜力尚未得到充分研究.
研究的目的:
- 研究马格诺林对炎症性肠病 (IBD) 的治疗作用.
- 阐明马格诺林在IBD中作用的潜在机制,重点关注铁和巨分化.
主要方法:
- 在体内和体外结肠炎模型中使用硫酸德克斯 (DSS) 建立.
- 利用生物信息学分析来识别潜在的磁林标,并评估与铁死相关的基因表达.
- 采用了qRT-PCR,免疫光染色,流细胞计,ELISA和西部涂抹来评估磁对铁,炎症和巨细胞表型的影响.
主要成果:
- 马格诺林 (5 mg/kg) 显著缓解了DSS诱导的大肠炎症状,并减少了小鼠的炎症.
- 生物信息学确定了阿拉基酸5-脂氧酶 (ALOX5) 作为一个关键标; 磁诺林抑制了ALOX5的表达.
- 马格诺林促进了M2巨细胞的两极分化,同时抑制了促炎因素 (IL-6,TNF-α) 并没有影响GPX4.
结论:
- 马格诺林通过抑制ALOX5介导的铁化,证明了IBD的显著治疗潜力.
- 马格诺林通过将巨细胞两极分化从M1变为M2表型来调节免疫反应.
- 这些发现表明,用于IBD的新型治疗策略,利用磁的抗炎和阻断ferroptosis的特性.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
01:17Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170